Physician profile
Weber Chen
NPI 1679504393
$26,740.22
in general payments reported to CMS, 2019-2025
81 companies · $6,268 in 2025
The $6,268 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,353 · 2020: $1,817 · 2021: $1,388 · 2022: $3,976 · 2023: $5,697 · 2024: $5,240 · 2025: $6,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,993.73 |
| Education | $212.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,237.58 | 2019-2025 | Erleada, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals Lp | $2,178.16 | 2019-2025 | Enhertu, Lynparza, Tagrisso |
| Pfizer INC. | $1,736.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,163.46 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Array Biopharma INC | $945.20 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $913.27 | 2019-2025 | Venclexta, Tecentriq, Erivedge |
| Gilead Sciences, INC. | $908.04 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $887.80 | 2019-2025 | |
| Amgen INC. | $809.83 | 2019-2025 | Lumakras, Vectibix, Nplate |
| Glaxosmithkline, LLC. | $806.85 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Celgene Corporation | $794.30 | 2020-2025 | Reblozyl, Opdualag, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $744.54 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $730.99 | 2019-2025 | Opdualag, Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $721.49 | 2019-2025 | |
| Genzyme Corporation | $681.46 | 2019-2025 |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $650.59 | 2021-2025 | Cabometyx |
| Eisai INC. | $517.56 | 2019-2025 | |
| Lilly USA, LLC | $500.93 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.20 | 2019-2025 | Gilotrif |
| Incyte Corporation | $496.11 | 2019-2025 | Jakafi, Niktimvo, Pemazyre |
| Ipsen Biopharmaceuticals, INC | $471.49 | 2022-2025 | Somatuline Depot, Onivyde |
| Regeneron Healthcare Solutions, INC. | $457.87 | 2020-2025 | Libtayo |
| Astellas Pharma US INC | $428.27 | 2019-2024 | Xtandi |
| Emd Serono, INC. | $373.95 | 2019-2025 | Bavencio |
| Abbvie INC. | $367.85 | 2022-2025 | Venclexta |
| Karyopharm Therapeutics INC. | $340.29 | 2020-2024 | Xpovio |
| Daiichi Sankyo INC. | $332.19 | 2020-2025 | Enhertu |
| Taiho Oncology, INC. | $315.04 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $303.75 | 2023-2025 | Orgovyx |
| Jazz Pharmaceuticals INC. | $280.43 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $252.48 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Kite Pharma, INC. | $244.21 | 2019-2025 | Yescarta |
| Tersera Therapeutics LLC | $241.75 | 2023-2025 | Zoladex, Xermelo |
| Pharmaessentia USA Corporation | $219.36 | 2022-2024 | Besremi |
| Seagen INC. | $217.15 | 2020-2023 | Padcev |
| Sun Pharmaceutical Industries INC. | $211.44 | 2019-2025 | Yonsa |
| Beigene USA, INC. | $199.12 | 2020-2025 | Brukinsa, Tevimbra |
| Janssen Scientific Affairs, LLC | $144.81 | 2023 | Erleada |
| Alnylam Pharmaceuticals INC. | $142.04 | 2022-2023 | Givlaari |
| Aveo Pharmaceuticals, INC. | $133.83 | 2021-2023 | Fotivda |
| Blueprint Medicines Corporation | $126.45 | 2020-2023 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $108.78 | 2019-2022 | |
| Angiodynamics, INC. | $102.75 | 2019 | |
| Mirati Therapeutics, INC. | $100.82 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $100.05 | 2023-2025 | Orserdu |
| Immunogen, INC. | $96.67 | 2023-2024 | Elahere, Elahere |
| Ge Healthcare | $91.58 | 2022 | |
| Kyowa Kirin, INC. | $88.94 | 2023-2025 | Poteligeo |
| Sobi, INC | $88.66 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $78.79 | 2023-2025 | Pyrukynd |
| Springworks Therapeutics, INC. | $74.51 | 2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $74.16 | 2024-2025 | |
| Novocure INC. | $72.43 | 2024-2025 | Optune, Optune Lua (Novottf-200t), Optune Gio |
| Azurity Pharmaceuticals, INC. | $70.50 | 2025 | Danziten |
| Morphosys, US INC. | $69.13 | 2021-2023 | Monjuvi |
| Legend Biotech USA INC. | $65.46 | 2024-2025 | Carvykti |
| Tesaro, INC. | $58.62 | 2019 | |
| Foundation Medicine, INC. | $54.27 | 2020-2021 | |
| Tolmar Pharmaceuticals, INC. | $46.99 | 2020 | |
| Rigel Pharmaceuticals, INC. | $46.23 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Clovis Oncology, INC. | $45.80 | 2020 | |
| Myovant Sciences INC. | $45.32 | 2021-2022 | |
| Verastem, INC. | $33.34 | 2019 | |
| Vivus LLC | $31.05 | 2022-2023 | Pancreaze |
| Mayne Pharma Commercial LLC | $27.73 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $27.53 | 2024 | Trelstar |
| Octapharma USA, INC. | $27.34 | 2025 | Panzyga |
| Tempus Ai, INC | $26.78 | 2024 | Xt Cdx |
| Acrotech Biopharma INC. | $24.12 | 2024 | Beleodaq |
| Mylan Institutional INC. | $23.18 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $22.54 | 2023 | Firdapse |
| Global Blood Therapeutics, INC. | $21.85 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $21.38 | 2024 | Akynzeo |
| Dova Pharmaceuticals | $21.25 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.59 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $20.08 | 2019 | |
| Advanced Accelerator Applications | $18.21 | 2020 | |
| Epizyme, INC. | $17.99 | 2022 | |
| Sirtex Medical INC | $17.93 | 2023 | Sir-Spheres Microspheres |
| Tolmar, INC. | $16.13 | 2023 | |
| Myriad Genetic Laboratories, INC. | $15.60 | 2024 | Myrisk |
Drugs and devices associated with these payments
Erleada $995Enhertu $982Keytruda $858Braftovi $793Mektovi $747Lorbrena $722Lynparza $722Orgovyx $517Xalkori $501Carvykti $415Tecvayli $405Onivyde $403Somatuline Depot $403Jakafi $398Ibrance $393Trodelvy $387Libtayo $364Zejula $363Jemperli $363Rybrevant $360Venclexta $350Xtandi $343Verzenio $342Jaypirca $304Elahere $295Tukysa $285Darzalex $279Cabometyx $277Opdualag $272Kisqali $270Lenvima $259Welireg $244Ninlaro $231Gilotrif $227Akeega $227Balversa $227Qinlock $227Inqovi $216Lonsurf $216Reblozyl $211Elrexfio $209Zoladex $205Tagrisso $204Retevmo $202Nubeqa $196Imfinzi $195Scemblix $194Zepzelca $170Iclusig $164Opdivo $160Talvey $157Besremi $152Adcetris $152Xpovio $135Stivarga $132Sarclisa $132Yonsa $132Brukinsa $129Inlyta $119Odomzo $108Talzenna $106Calquence $101Krazati $101Orserdu $100Vitrakvi $90.17Fruzaqla $89.01Poteligeo $88.94Doptelet $88.66Tecentriq $86.41Lumakras $85.13Ojjaara $78.15Xofigo $76.51Mekinist $75.39Pomalyst $74.67Danziten $70.50Givlaari $70.32Enjaymo $65.59Tevimbra $64.40Bosulif $61.18Pyrukynd $60.73Nplate $60.60Vectibix $60.60Xgeva $60.60Ogsiveo $59.70Jevtana $58.80Romvimza $58.35Padcev $52.63Ziihera $49.07Ayvakit $46.98Monjuvi $46.32Bavencio $40.78Yescarta $40.62Fotivda $39.93Comirnaty $37.02Xermelo $36.46Cablivi $33.98Erivedge $33.17Niktimvo $28.49Tabrecta $28.32Lutathera $27.79
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weber Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.